Please check your internet connection and try again.
# Urimax (tamsulosin)
## Overview
- Alpha-1 adrenergic receptor antagonist, selective for prostate/urethral smooth muscle.
- Used to relax bladder neck and prostate, improving urine flow.
## Primary Indications
- **Benign prostatic hyperplasia (BPH)** – treatment of lower urinary tract symptoms.
- **Off-label:** distal ureteral stones (to facilitate passage), voiding dysfunction in children (limited evidence).
## Adult Dosing
- **Initial:** 0.4 mg orally once daily, approximately 30 minutes after the same meal each day (e.g., breakfast).
- **Titration:** if inadequate response after 2–4 weeks, may increase to 0.8 mg once daily.
- **Maximum dose:** 0.8 mg daily.
## Pediatric Dosing
- **Not established** for BPH (no indication in children).
- **Off-label (expert guidance only):** For ureteral stones or voiding dysfunction – typical weight-based dosing 0.1–0.2 mg/kg/day once daily, but varies by local protocol. **Do not use without specialist supervision.**
## Dose Adjustments
- **Renal impairment:** no adjustment for mild-to-moderate; caution in severe (CrCl <10 mL/min) – limited data; use with monitoring.
- **Hepatic impairment:** contraindicated in severe hepatic impairment (Child-Pugh C); no adjustment in mild-to-moderate, but use caution.
- **Elderly:** No specific dose adjustment; watch for orthostatic hypotension.
## Contraindications
- Hypersensitivity to tamsulosin or any component.
- History of orthostatic hypotension.
- Severe hepatic impairment.
- Combination with other alpha-blockers for BPH (unless specifically prescribed).
## Adverse Effects
- **Common:** dizziness, rhinitis, asthenia, abnormal ejaculation (retrograde or decreased volume), headache, postural hypotension (especially first dose).
- **Serious:** intraoperative floppy iris syndrome (IFIS) during cataract surgery; syncope; angioedema; priapism.
- **Note:** May cause orthostatic hypotension – advise patients to rise slowly.
## Key Drug Interactions
- **CYP3A4 inhibitors** (e.g., ketoconazole, ritonavir) → ↑ tamsulosin levels; avoid or reduce dose.
- **Phosphodiesterase-5 inhibitors** (e.g., sildenafil, tadalafil) → additive hypotension; separate dosing by at least 4 hours.
- **Other alpha-blockers, antihypertensives** → increased hypotensive effect.
- **Warfarin** – monitor INR if co-administered (uncertain significance).
## Monitoring
- **Blood pressure** (especially after first dose and dose increases) – assess for orthostatic hypotension.
- **Symptoms of BPH** – IPSS score improvement, flow rate.
- **Cataract surgery history** – inquire before surgery; IFIS risk continues after discontinuation? (Variable; some recommend stopping 2 weeks before, but no clear consensus).
## Clinical Pearls
- **Administer with a meal** – food reduces peak concentration by about 30% but decreases variability; take 30 minutes after same meal daily.
- **First-dose effect** – orthostatic hypotension most likely on the first day; advise taking dose at bedtime initially.
- **IFIS warning** – inform ophthalmologist about tamsulosin use prior to cataract surgery.
- **No effect on PSA** – tamsulosin does not lower prostate-specific antigen; do not adjust PSA interpretation.
- Do not crush or chew capsules (extended-release formulation).
---
*Educational disclaimer: This information is for general reference and does not replace clinical judgment. Dosing and safety may vary based on local protocols, patient-specific factors, and evolving evidence. Always verify against current prescribing information (e.g., manufacturer labeling, national formulary) before use.*
